Siegl PK - Search Results

1

Torcetrapib-induced blood pressure elevation is independent of CETP inhibition and is accompanied by increased circulating levels of aldosterone.

Forrest MJ, Bloomfield D, Briscoe RJ, Brown PN, Cumiskey AM, Ehrhart J, Hershey JC, Keller WJ, Ma X, McPherson HE, Messina E, Peterson LB, Sharif-Rodriguez W, Siegl PK, Sinclair PJ, Sparrow CP, Stevenson AS, Sun SY, Tsai C, Vargas H, Walker M 3rd, West SH, White V, Woltmann RF. Forrest MJ, et al. Among authors: siegl pk. Br J Pharmacol. 2008 Aug;154(7):1465-73. doi: 10.1038/bjp.2008.229. Epub 2008 Jun 9. Br J Pharmacol. 2008. PMID: 18536749 Free PMC article.

2

Lack of beneficial effects of growth hormone treatment in conscious dogs during development of heart failure.

Shen YT, Woltmann RF, Appleby S, Prahalada S, Krause SM, Kivilghn SD, Johnson RG, Siegl PK, Lynch JJ. Shen YT, et al. Among authors: siegl pk. Am J Physiol. 1998 Feb;274(2):H456-66. doi: 10.1152/ajpheart.1998.274.2.H456. Am J Physiol. 1998. PMID: 9486248

3

In vivo pharmacology of an angiotensin AT1 receptor antagonist with balanced affinity for AT2 receptors.

Kivlighn SD, Zingaro GJ, Gabel RA, Broten TP, Chang RS, Ondeyka DL, Mantlo NB, Gibson RE, Greenlee WJ, Siegl PK. Kivlighn SD, et al. Among authors: siegl pk. Eur J Pharmacol. 1995 Dec 29;294(2-3):439-50. doi: 10.1016/0014-2999(95)00564-1. Eur J Pharmacol. 1995. PMID: 8750704

4

In vitro pharmacology of L-158,809, a new highly potent and selective angiotensin II receptor antagonist.

Chang RS, Siegl PK, Clineschmidt BV, Mantlo NB, Chakravarty PK, Greenlee WJ, Patchett AA, Lotti VJ. Chang RS, et al. Among authors: siegl pk. J Pharmacol Exp Ther. 1992 Jul;262(1):133-8. J Pharmacol Exp Ther. 1992. PMID: 1625192

5

Safety pharmacology in 2010 and beyond: survey of significant events of the past 10 years and a roadmap to the immediate-, intermediate- and long-term future in recognition of the tenth anniversary of the Safety Pharmacology Society.

Bass AS, Vargas HM, Valentin JP, Kinter LB, Hammond T, Wallis R, Siegl PK, Yamamoto K. Bass AS, et al. Among authors: siegl pk. J Pharmacol Toxicol Methods. 2011 Jul-Aug;64(1):7-15. doi: 10.1016/j.vascn.2011.05.006. Epub 2011 Jun 12. J Pharmacol Toxicol Methods. 2011. PMID: 21689769 Review.

6

In vivo pharmacology of L-158,809, a new highly potent and selective nonpeptide angiotensin II receptor antagonist.

Siegl PK, Chang RS, Mantlo NB, Chakravarty PK, Ondeyka DL, Greenlee WJ, Patchett AA, Sweet CS, Lotti VJ. Siegl PK, et al. J Pharmacol Exp Ther. 1992 Jul;262(1):139-44. J Pharmacol Exp Ther. 1992. PMID: 1625193

7

In vitro pharmacology of an angiotensin AT1 receptor antagonist with balanced affinity for AT2 receptors.

Chang RS, Lotti VJ, Chen TB, O'Malley SS, Bendesky RJ, Kling PJ, Kivlighn SD, Siegl PK, Ondeyka D, Greenlee WJ, et al. Chang RS, et al. Among authors: siegl pk. Eur J Pharmacol. 1995 Dec 29;294(2-3):429-37. doi: 10.1016/0014-2999(95)00563-3. Eur J Pharmacol. 1995. PMID: 8750703

8

Comparison of electrocardiographic analysis for risk of QT interval prolongation using safety pharmacology and toxicological studies.

Guth BD, Bass AS, Briscoe R, Chivers S, Markert M, Siegl PK, Valentin JP. Guth BD, et al. Among authors: siegl pk. J Pharmacol Toxicol Methods. 2009 Sep-Oct;60(2):107-16. doi: 10.1016/j.vascn.2009.05.006. Epub 2009 May 24. J Pharmacol Toxicol Methods. 2009. PMID: 19470407 Review.

9

In vivo receptor occupancy of the angiotensin II receptor by nonpeptide antagonists: relationship to in vitro affinities and in vivo pharmacologic potency.

Beauchamp HT, Chang RS, Siegl PK, Gibson RE. Beauchamp HT, et al. Among authors: siegl pk. J Pharmacol Exp Ther. 1995 Feb;272(2):612-8. J Pharmacol Exp Ther. 1995. PMID: 7853174

10

Pharmacological properties of J-104132 (L-753,037), a potent, orally active, mixed ETA/ETB endothelin receptor antagonist.

Nishikibe M, Ohta H, Okada M, Ishikawa K, Hayama T, Fukuroda T, Noguchi K, Saito M, Kanoh T, Ozaki S, Kamei T, Hara K, William D, Kivlighn S, Krause S, Gabel R, Zingaro G, Nolan N, O'Brien J, Clayton F, Lynch J, Pettibone D, Siegl P. Nishikibe M, et al. J Pharmacol Exp Ther. 1999 Jun;289(3):1262-70. J Pharmacol Exp Ther. 1999. PMID: 10336515

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

87 results

Search Page